Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours

Gut

Volumn 38, Issue 3, 1996, Pages 430-438

  Arnold, R ^a,c   Trautmann, M E ^a   Creutzfeldt, W ^c,d   Benning, R ^b   Benning, M ^b   Neuhaus, C ^a   Jurgensen R ^b   Stein, K ^b   Schafer H ^b   Bruns, C ^f   Dennler, H J ^e  

^a Div of Gastroenterol and Metab

^b Department of Radiology ^*

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e Medical Department   (Germany)

^f Preclinical Research   (Switzerland)

Author keywords

Endocrine tumours; Octreotide; Side effects; Symptomatic response; Tumour growth inhibition

Indexed keywords

OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; ENDOCRINE TUMOR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREAS TUMOR; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMACH TUMOR; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR GROWTH;

ADENOMA, ISLET CELL; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOID TUMOR; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PANCREATIC NEOPLASMS; PROSPECTIVE STUDIES;

EID: 0029866470     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.38.3.430     Document Type: Article

References (46)

1. Arnold R. Therapeutic strategies in the management of endocrine GEP tumours. Eur J Clin Invest 1990; 20 (suppl 1): 82-90.
2. Ch'ng JL, Anderson JV, Williams SJ, Carr DH, Bloom SR. Remission of symptoms during long-term treatment of metastatic pancreatic endocrine tumours with long-acting somatostatin analogue. BMJ 1985; ii: 981-2.
3. Kvols LK, Buck M, Moertel ChG, Schutt AJ, Rubin J, O'Connell MJ, et al. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med 1987; 107: 162-8.
4. Maton PN, Gardner JD, Jensen RT. Use of long-acting somatostatin analogue SMS 201-995 in patients with pancreatic islet-cell tumours. Dig Dis Sci 1989; 34 (suppl): 285-91.
5. Buchanan KD. Effects of sandostatin on neuro-endocrine tumours of the gastrointestinal system. Recent Results Cancer Res 1993; 129: 45-55.
6. Creutzfeldt W, Bartsch HH, Jacubaschke U, Stöckmann F. Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide. Acta Oncol 1991; 30: 529-36.
7. Arnold R, Neuhaus Ch, Benning R, Schwerk WB, Trautmann ME, Joseph K, et al. Somatostatin analog sandostatin and inhibition of tumour growth in patients with metastatic endocrine gastroenteropancreatic tumours. World J Surg 1993; 17: 511-9.
8. Rothmund M, Stinner B, Arnold R. Endocrine pancreatic carcinoma. Eur J Surg Oncol 1991; 17: 191-9.
9. Allison DJ, Jordan H, Hennessy O. Therapeutic embolization of the hepatic artery: a review of 75 procedures. Lancet 1985; i: 595-9.
10. Carrasco CH, Charnsangavej Ch, Ajani J, Samaan NA, Richli W, Wallace S. The carcinoid syndrome: palliation by hepatic artery embolization. Am J Radiol 1986; 147: 149-54.
11. Moertel CG, Hanley JA, Johnson LA. Streptozotocin alone compared with streptozotocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980; 303: 1189-94.
12. Sridhar KS, Holland JF, Brown JC, Cohen JM, Ohnuma T. Doxorubicin plus cisplatin in the treatment of apudomas. Cancer 1985; 55: 2634-7.
13. Kvols LK, Buck M. Chemotherapy of endocrine malignancies: a review. Semin Oncol 1987; 14: 343-83.
14. Von Schrenck T, Howard JM, Doppman JL, Norton JA, Maton PN, Smith FP, et al. Prospective study of chemotherapy in patients with metastatic gastrinoma. Gastroenterology 1988; 94: 1326-34.
15. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-32.
16. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozotocin-doxorubicin, streptozotocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326: 519-23.
17. Makowka L, Tzakis AG, Mazzaferro V, Teperman L, Demetris AJ, Iwatsuki S, et al. Transplantation of the liver for metastatic endocrine rumours of the intestine and pancreas. Surg Gynecol Obstet 1989; 168: 107-11.
18. Johnson LA, Lavin P, Moertel CG, Weiland L, Dayal Y. Carcinoids: the association of histologic growth pattern and survival. Cancer 1983; 51: 882-9.
19. Öberg K, Funa K, Alm G. Effects of leucocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumours and carcinoid syndrome. N Engl J Med 1983; 309: 129-33.
20. Öberg K, Norheim I, Lind E, Alm G, Lundquist G, Wide L, et al. Treatment of malignant carcinoid rumours with human leucocyte interferon: long-term results. Cancer Treat Rev 1986; 11: 1297-304.
21. Smith DB, Scarffe JH, Wagstaff J, Johnston RJ. Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumour. Cancer Treat Rep 1987; 7: 1265-6.
22. Gordon Ph. NIH Conference: Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumours of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. Ann Intern Med 1989; 110: 35-50.
23. Saltz L, Trochanowsky G, Buckley M, Heffernan B, Niedzwicki D, Tao Y, Kelsen D. Octreotide as an anti-neoplastic agent in the treatment of functional and non-functional neuroendocrine tumours. Cancer 1993; 72: 244-8.
24. Hanssen LE, Schrumpf E, Kolbenstredt AN, Tausjo J, Dolva LO. Recombinant alpha-2 interferon with or without hepatic artery embolization in the treatment of midgut carcinoid tumours - a preliminary report. Acta Oncol 1989; 28: 439-43.
25. Joensuu H, Kätka K, Kujari H. Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide. Acta Endocrinol (Copenh) 1992; 126: 184-5.
26. Nold R, Frank M, Kajdan U, Trost U, Klose KH, Arnold R. Kombinierte Behandlung metastasierter endokriner Tumoren des Gastrointestinaltraks mit Octreotid und Interferon-Alpha. Z Gastroenterol 1994; 32: 193-7.
27. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315: 663-6.
28. Vinik A, Moattari AR. Use of somatostatin analogue in management of carcinoid syndrome. Dig Dis Sci 1989; 34 (suppl): 14-27S.
29. Ruskoné A, René E, Chayvialle JA, Bonin N, Pignal F, Kremer M, et al. Effect of somatostatin on diarrhoea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. Dig Dis Sci 1982; 27: 459-66.
30. Maton PN, O'Dorisio ThM, Howe BA, McArthur KE, Howard JM, Cherner JA, et al. Effect of long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. N Engl J Med 1985; 312: 17-21.
31. Santangelo WC, O'Dorisio ThM, Kim JG, Severino G, Krejs G. Pancreatic cholera syndrome: effect of a synthetic somatostatin analogue on intestinal water and ion transport. Ann Intern Med 1985; 103: 363-7.
32. Boden G, Ryan IG, Eisenschmidt BL, Shelmet JJ, Owen OE. Treatment of inoperable glucagonoma with long-acting somatostatin analogue SMS 201-995. N Engl J Med 1986; 314: 1686-9.
33. Evers BM, Parekh D, Townsend CM, Thompson JC. Somatostatin and analogues in the treatment of cancer. A review. Ann Surg 1991; 213: 190-8.
34. Kraenzlin ME, Ch'ng JC, Wood SM, Bloom SR. Can inhibition of hormone secretion be associated with endocrine tumour shrinkage? Lancet 1983; ii: 1501-4.
35. Kraenzlin ME, Ch'ng JC, Wood SM, Carr DJ. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 1985; 88: 185-7.
36. Clements D, Elias E. Regression of metastatic VIPoma with somatostatin analogue SMS 201-995. Lancet 1985; i: 874-5.
37. Shepherd JJ, Senator GB. Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201-995. Lancet 1986; ii: 574.
38. Wiedenmann B, Räth U, Rädsch R, Becker F, Kommerell B. Tumour regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995. Klin Wochenschr 1988; 66: 75-7.
39. Capella C, Heitz PhU, Höfler H, Solcia E, Klöppel G. Revised classification of neuroendocrine rumours of the lung, pancreas and gut. Digestion 1994; 55 (suppl 3): 11-23.
40. Bruns Ch, Dietl MM, Palaccos JM, Pless J. Identification and characterization of somatostatin receptors in neonatal rat long bones. Biochem J 1990; 265: 39-45.
41. Joseph K, Stapp J, Reinecke J, Höffken H, Benning R, Neuhaus Ch, et al. Rezeptorszintigraphie bei endokrinen gastroentero-pankreatischen Tumoren. Dtsch Med Wochenschr 1992; 117: 1025-8.
42. Orbuch M, Doppman JL, Strader DB, Fishbeyn VA, Benya RV, Metz DC, et al. Imaging for pancreatic endocrine tumour localization: recent advances. In: Mignon M, Jensen RT, eds. Endocrine tumours of the pancreas. Basel: Karger, 1995; 23: 268-81.
43. Reubi JC. Somatostatin receptors in the gastrointestinal tract in health and disease. Yale J Biol Med 1992; 65: 505-18.
44. Lewin MJ. The somatostatin receptor in the GI tract. Ann Rev Physiol 1992; 54: 455-68.
45. Deguchi H, Deguchi K, Tsukada T, Murashima S, Iwasaki E, Tsuda M, et al. Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide. Intern Med 1994; 31: 100-2.
46. Anthony LB, Winn SD, Johnson DH, Oates JA. Chronic high dose octreotide in neuroendocrine neoplasms. Ann Oncol 1994; 5 (suppl 5): A267.